Cell and Gene Therapy Business Outlook: Volume 1, Issue 14
Don't miss our new twice-monthly publication dedicated to cell and gene therapy. Cell and Gene Therapy Business Outlook offers the following:
- Market Sizing and Forecasting of CAGT Markets
- Executive News Summaries
- Deals Between CAGT Companies Tracked
- Financing
- Trends in the Industry
- Important Science That Will Shape Tomorrow’s Business
- Company Profiling and Quarterly Results Summaries
- Updates on Pipelines and Important Clinical Trials
- Cell and Gene Therapy Tools
- Cell and Gene Therapy CMOs
- And More
-
Untitled Chapter
-
Market Analysis
-
Focus on Cell and Gene Therapy for Liver Diseases
-
Overview of Cell and Gene Therapy for Liver Diseases
-
Market Outlook
-
Products in Development
-
Regional Analysis
-
Top Company Briefs
-
Alnylam Pharmaceuticals
-
Bristol-Myers Squibb
-
Arrowhead Pharmaceuticals
-
Steminent Biotherapeutics
-
Executive News Brief
-
Recent developments in cell and gene therapy
-
Recent Funding Deals
-
2022 Starts with Two Hundred-Million Dollar Deals
-
Cell and Gene Therapy Market News and News Analysis
-
SalioGen Therapeutics Raises $115 Million for Gene Coding Platform
-
Synthetic Biology Company Senti Bio to Go Public with SPAC Merger
-
Cell and Gene Therapy Expert Interviews
-
INTERVIEW: Amanda Cashin, Illumina for Startups
-
Recent CGT Deal Activity
-
pdf - KC_Vol. 1 Issue 14 - CELL AND GENE THERAPY BUSINESS OUTLOOK.pdf